SLU PP332

Product research information

SLU-PP-332 is a synthetic compound with the molecular formula C₁₈H₁₄N₂O₂. It is distinct from amino acid-based peptides, functioning instead as a direct nuclear receptor agonist. It was developed to probe the physiological roles of Estrogen-Related Receptors (ERRs), which are orphan nuclear receptors involved in the regulation of cellular energy metabolism.

Primary research focuses on the interaction between SLU-PP-332 and the ERRα, ERRβ, and ERRγ receptors. Upon binding, SLU-PP-332 is observed to stabilize the active conformation of these receptors, promoting the recruitment of coactivators such as PGC-1α (Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha).

In laboratory studies involving murine models, SLU-PP-332 has been investigated for its ability to enhance mitochondrial respiration. Data indicates that the compound may upregulate the expression of genes associated with oxidative phosphorylation and fatty acid metabolism. Researchers have noted that administration in mice resulted in an increase in type IIa oxidative muscle fibers, leading to the classification of this compound as an “exercise mimetic” in scientific literature.

Further investigation suggests that SLU-PP-332 may influence lipid metabolism. Studies utilizing diet-induced obese mice have observed changes in energy expenditure and fat mass accumulation without alterations in food intake or physical activity levels. These findings suggest a potential pathway for modulating metabolic profiles through direct receptor activation.

References

1. Billon, C., et al. (2023). “Synthetic ERRα/β/γ Agonist Induces an ERRα-Dependent Acute Aerobic Exercise Response and Enhances Exercise Capacity.” ACS Chemical Biology, 18(4), 756-771.
2. Billon, C., et al. (2024). “A Synthetic ERR Agonist Alleviates Metabolic Syndrome.” Journal of Pharmacology and Experimental Therapeutics, 388(2), 232-240.
3. Fan, W., & Evans, R. M. (2015). “Exercise Mimetics: Impact on Health and Performance.” Cell Metabolism, 22(3), 399-413.